A study on Sunday found the Oxford University jab had ‘minimal effect’ in preventing mild disease caused by the strain, suggesting vaccinated people may still be able to catch and spread it.
Professor Mike Tildesley, an infectious disease expert at Warwick University and member of SAGE, said the finding could have ‘significant implications’ on Britain’s lockdown-easing plans.
He told the
Despite the fresh findings, one of South Africa’s top infectious disease experts said today the Oxford jab should still protect against severe disease.
Professor Salim Abdool Karim, head of the country’s Covid response unit, pointed to the trial of Johnson and Johnson’s jab, which uses the same technology as Oxford’s and was shown to be 100 per cent effective at stopping hospitalisations and deaths.
UK ministers today urged Brits to keep faith in the Oxford vaccine. Health minister Edward Argar told the public not to lose sight of the main purpose of vaccines – which is to drive down hospitalisations and deaths to manageable levels.
The comments were echoed by vaccines minister Nadhim Zahawi last night, who said preventing severe disease was the ‘vitally important’ factor for the vaccines.
So far there have only been 147 confirmed cases of the South African variant in Britain. But this is likely to be a vast underestimate because up until last week officials were only analysing 10 per cent of random positive swabs.
Scientists say the true number of cases is likely 10 to 20 times higher than the official count. No10 has deployed extra testing into more than 10 areas of England where the South African strain is thought to be spreading in the community.
Officials will analyse every positive result produced in postcodes in London, Kent, Hertfordshire, Surrey, Lancashire and Walsall in the West Midlands.
Professor Mike Tildesley, an infectious disease expert and member of the Sage advisory panel, said Britain could face more lockdown restrictions if the South African Covid variant continues to spread
The three Covid variants causing international alarm emerged in Britain, South Africa and Brazil
Government sources said last night that there was ‘no indication’ the easing of
Yesterday’s study suggests the South African variant may still be able to spread among people vaccinated with the Oxford jab. But if only a tiny fraction of patients fall ill enough to need hospital care it suggests the NHS will not be at threat of being overwhelmed.
Mr Zahawi highlighted the low levels of the South African variant means it is unlikely to overtake the Kent one and become the dominant strain in the UK any time soon.
A tweaked version of the Oxford vaccine that targets the new strain is already in development and should be ready by August. The current vaccine rollout should buy jab-makers time until the new booster shots are available.
Mr Argar said this morning there was ‘no evidence’ that the Oxford/AstraZeneca vaccine is not effective at preventing severe illness from coronavirus.
He told Sky News: ‘There is no evidence that this vaccine is not effective in preventing hospitalisation, severe illness and death, which is ultimately what we’re seeking with these vaccines.’
The minister noted that the ‘dominant strains in this country are not the South African strain’, with ‘only a small number of cases of that’.
He added that South Africa’s suspension of the rollout of the vaccine is only ‘temporary’ at this stage.
The study that found the Oxford jab had a ‘minimal effect’ in protecting against mild disease caused by the variant involved 2,000 volunteers, most of whom were young and healthy with an average age of 31.
The study also appeared to show that the South African mutations will allow for ongoing transmission of the virus in vaccinated populations.
Out of 865 people vaccinated with two doses of the Oxford vaccine, 19 contracted the new variant, and out of 884 in the group given a placebo, 23 contracted the disease. Two thirds of the cases were of mild illness, and one third moderate. There were no severe cases.
The researchers also found that previous infection with ‘original’ coronavirus did not protect against contracting the South African variant.
Oxford University said the study did not assess levels of protection against moderate to severe disease, hospital admission or death because the target population was at such low risk.
A spokesman for AstraZeneca said: ‘We do believe our vaccine will still protect against severe disease, as neutralising antibody activity is equivalent to other Covid-19 vaccines that have demonstrated activity against more severe disease, particularly when the dosing interval is optimised to eight to 12 weeks.’
The spokesman added that other immune responses, such as T-cell responses, may have a role in protecting against disease, and initial data suggests these may stay the same with the variant.
Professor Robin Shattock, who is leading Covid-19 vaccine research at Imperial College London, urged caution about the study’s findings.
‘It’s a very small study with just over 2,000 people,’ he told BBC Breakfast.
‘But it is concerning to some extent that we’re seeing that it’s not effective against mild or moderate disease.’
Professor Andrew Pollard, chief investigator on the Oxford trial, said: ‘This study confirms that the coronavirus will find ways to continue to spread in vaccinated populations, as expected.
‘But, taken with the promising results from other studies in South Africa, vaccines may continue to ease the toll on healthcare systems by preventing severe disease.’
On Saturday, AstraZeneca said its vaccine provided good protection against the variant first discovered in Kent, which is now dominant in the UK. Early results suggest the Pfizer/BioNTech vaccine protects against the new variants.
Early results from Moderna suggest its vaccine is still effective against the South Africa variant.
Meanwhile, a booster jab that will help tackle the South African variant of
Professor Sarah Gilbert, lead researcher in the Oxford team, said current vaccines ‘have a reduction in efficacy against some of the variant viruses’.
But she added: ‘What that is looking like is that we may not be reducing the total number of cases but there’s still protection in that case against deaths, hospitalisations and severe disease.
‘That’s really important for healthcare systems, even if we are having mild and asymptomatic infections, to prevent people going into hospital with Covid would have a major effect.’
Don’t panic – Covid-19 injection will still keep you out of hospital even if you fall ill with South African variant, writes PROFESSOR HUGH PENNINGTON
A vaccine is not an impenetrable barrier in the body through which no virus can pass. It’s more like a superpower, which enables our immune systems to fight better, faster and stronger against an invader.
So the discovery that the Oxford-AstraZeneca (AZ) vaccine for Covid-19 is less effective against some new variants of
Just like the heroes in a blockbuster movie, we’re simply going to have to adapt our new superpowers.
News that the AZ jab has ‘limited efficacy’ against mild and moderate disease caused by the South African strain of the virus was treated yesterday in some quarters as a looming disaster.
Broadcaster and author Loyd Grossman receives the AstraZeneca vaccine at North Cotswold Hospital in Gloucestershire
It is not – and I say this not only as an academic with a lifetime’s experience in viruses and vaccines, but as an 82-year-old man who has had his first AZ injection.
This means I have a keen personal – as well as professional – interest in getting the facts straight.
Covid-19 attacks the body in two ways. It multiplies in the mouth, nose and throat, where it can exist without causing noticeable symptoms, yet spreads virulently.
The microscopic viral particles are then breathed in and out on droplets of saliva and mucus.
It can also invade the rest of the body. In the most serious cases, it attacks the lungs, causing breathing difficulties that can be fatal.
The discovery that the Oxford-AstraZeneca is less effective against some new variants of coronavirus than others is no cause for alarm, writes Professor Hugh Pennington (pictured)
It can also affect the heart and other vital organs including the kidneys. There is also mounting evidence to suggest it sometimes attacks the brain.
It is in cases such as these that patients often require hospital treatment, in turn driving the terrible fatality figures and threatening to overwhelm the NHS. And, crucially, it is these cases that the AZ vaccine prevents – even in its South African variant.
In order to wipe out Covid altogether, we need the vaccine to protect against mild and asymptomatic cases too because they are most likely to spread the illness.
Once these milder cases are prevented, the ‘R’ number will drop – that is, infection rates will plummet.
Tweaking the vaccine code in the laboratory, to ensure it works against the South African variant, ought not to be a major problem. I would expect the revised formula to be engineered within a week or so.
Of course, a whole series of logistical challenges exists beyond that – we have to acquire official approval and ratification, manufacture millions of new doses, then get them bottled and distributed.
A team of medical staff treat a patient with coronavirus at King’s College Hospital in London
Pictured: A health worker prepares the AstraZeneca/Oxford vaccine at the Mignot Hospital in Le Chesnay near Paris
When news of the vaccine first broke, I set a simple benchmark. To be deemed a success, the jabs had to be more effective against Covid than the annual flu vaccines have been. That sets a high standard.
In most years, flu jabs prevent infection at least 50 per cent of the time, even though the disease is constantly mutating.
Covid jabs have far outstripped that target. It may take the world years to eradicate Covid fully.
But we must not allow a small and entirely predictable setback to rattle our faith that life will soon be returning far closer to normal.
Hugh Pennington is emeritus professor of bacteriology at Aberdeen University
Tips to Find Low Priced Luxury Holiday Package Deals Fast